Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Cardiovascular Translational Research
Erschienen in: Journal of Cardiovascular Translational Research 3/2017

05.06.2017 | Original Article

Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview

verfasst von: Sanjiv J. Shah

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

There are few proven therapies for heart failure with preserved ejection fraction (HFpEF). The lack of therapies, along with increased recognition of the disorder and its underlying pathophysiology, has led to the acknowledgement that HFpEF is heterogeneous and is not likely to respond to a one-size-fits-all approach. Thus, HFpEF is a prime candidate to benefit from a precision medicine approach. For this reason, we have assembled a compendium of papers on the topic of precision medicine in HFpEF in the Journal of Cardiovascular Translational Research. These papers cover a variety of topics relevant to precision medicine in HFpEF, including automated identification of HFpEF patients; machine learning, novel molecular approaches, genomics, and deep phenotyping of HFpEF; and clinical trial designs that can be used to advance precision medicine in HFpEF. In this introductory article, we provide an overview of precision medicine in HFpEF with the hope that the work described here and in the other papers in this special theme issue will stimulate investigators and clinicians to advance a more targeted approach to HFpEF classification and treatment.
Literatur
1.
Shah, S. H., Arnett, D., Houser, S. R., & Ginsburg, G. S. (2016). Opportunities for the cardiovascular community in the precision medicine initiative. Circulation, 133, 226–231.CrossRefPubMed
2.
Shah, S. J., Katz, D. H., & Deo, R. C. (2014). Phenotypic spectrum of heart failure with preserved ejection fraction. Heart Failure Clinics, 10(3), 407–418.CrossRefPubMedPubMedCentral
3.
Bordicchia, M., Liu, D., Amri, E. Z., Ailhaud, G., Dessi-Fulgheri, P., Zhang, C., et al. (2012). Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. The Journal of Clinical Investigation, 122(3), 1022–1036.CrossRefPubMedPubMedCentral
4.
5.
Chirinos, J. A. (2017). Deep phenotyping of systemic arterial hemodynamics in HFpEF (part 2): clinical and therapeutic considerations. Journal of Cardiovascular Translational Research. doi:10.​1007/​s12265-017-9736-2.
6.
Chirinos, J. A. (2017). Deep phenotyping of systemic arterial hemodynamics in HFpEF (part 1): physiologic and technical considerations. Journal of Cardiovascular Translational Research. doi:10.​1007/​s12265-017-9735-3.
7.
Kao, D. P., Stevens, L. M., Hinterberg, M. A., & Gorg, C. (2017). Phenotype-specific association of single-nucleotide polymorphisms with heart failure and preserved ejection fraction: a genome-wide association analysis of the cardiovascular health study. Journal of Cardiovascular Translational Research. doi:10.​1007/​s12265-017-9729-1.
8.
Katz, D. H., Deo, R. C., Aguilar, F. G., Selvaraj, S., Martinez, E. E., Beussink-Nelson, L., et al. (2017). Phenomapping for the identification of hypertensive patients with the myocardial substrate for heart failure with preserved ejection fraction. Journal of Cardiovascular Translational Research. doi:10.​1007/​s12265-017-9739-z.
9.
Kriegel, A. J., Gartz, M., Afzal, M. Z., de Lange, W. J., Ralphe, J. C., & Strande, J. L. (2016). Molecular approaches in HFpEF: microRNAs and iPSC-Derived cardiomyocytes. Journal of Cardiovascular Translational Research. doi:10.​1007/​s12265-016-9723-z.
10.
Luo, Y., Ahmad, F. S., & Shah, S. J. (2017). Tensor factorization for precision medicine in heart failure with preserved ejection fraction. Journal of Cardiovascular Translational Research. doi:10.​1007/​s12265-016-9727-8.
11.
Jonnalagadda, S. R., Adupa, A. K., Garg, R. P., Corona-Cox, J., & Shah, S. J. (2017). Text mining of the electronic health record: an information extraction approach for the automated identification and subphenotyping of HFpEF patients for clinical trials. Journal of Cardiovascular Translational Research. (In press).
12.
Shah, S. J. (2017). Innovative clinical trial designs for precision medicine in heart failure with preserved ejection fraction. Journal of Cardiovascular Translational Research. (In press).
13.
Redfield, M. M. (2016). Heart failure with preserved ejection fraction. The New England Journal of Medicine, 375(19), 1868–1877.CrossRefPubMed
14.
15.
Oktay, A. A., Rich, J. D., & Shah, S. J. (2013). The emerging epidemic of heart failure with preserved ejection fraction. Current Heart Failure Reports, 10(4), 401–410.CrossRefPubMed
16.
Shah, S. J., Heitner, J. F., Sweitzer, N. K., Anand, I. S., Kim, H. Y., Harty, B., et al. (2013). Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation. Heart Failure, 6(2), 184–192.CrossRefPubMed
17.
Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006). Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England Journal of Medicine, 355(3), 251–259.CrossRefPubMed
18.
Sharma, K., & Kass, D. A. (2014). Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circulation Research, 115(1), 79–96.CrossRefPubMedPubMedCentral
19.
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., et al. (2014). Spironolactone for heart failure with preserved ejection fraction. The New England Journal of Medicine, 370(15), 1383–1392.CrossRefPubMed
20.
Adamson, P. B., Abraham, W. T., Bourge, R. C., Costanzo, M. R., Hasan, A., Yadav, C., et al. (2014). Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circulation. Heart Failure, 7(6), 935–944.CrossRefPubMed
21.
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., et al. (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet, 362(9386), 777–781.CrossRefPubMed
22.
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., et al. (2008). Irbesartan in patients with heart failure and preserved ejection fraction. The New England Journal of Medicine, 359(23), 2456–2467.CrossRefPubMed
23.
Redfield, M. M., Chen, H. H., Borlaug, B. A., Semigran, M. J., Lee, K. L., Lewis, G., et al. (2013). Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA, 309(12), 1268–1277.CrossRefPubMed
24.
Redfield, M. M., Anstrom, K. J., Levine, J. A., Koepp, G. A., Borlaug, B. A., Chen, H. H., et al. (2015). Isosorbide mononitrate in heart failure with preserved ejection fraction. The New England Journal of Medicine, 373(24), 2314–2324.CrossRefPubMedPubMedCentral
25.
Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., et al. (2016). Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation, 134(1), 73–90.CrossRefPubMedPubMedCentral
26.
Kitzman, D. W., & Shah, S. J. (2016). The HFpEF obesity phenotype: the elephant in the room. Journal of the American College of Cardiology, 68(2), 200–203.CrossRefPubMed
27.
Borlaug, B. A. (2014). The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews. Cardiology, 11(9), 507–515.CrossRefPubMed
28.
Shah, S. J., Cogswell, R., Ryan, J. J., & Sharma, K. (2016). How to develop and implement a specialized heart failure with preserved ejection fraction clinical program. Current Cardiology Reports, 18(12), 122.CrossRefPubMed
29.
Shah, S. J. (2013). Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter. Journal of the American College of Cardiology, 62(15), 1339–1342.CrossRefPubMed
30.
Burkhoff, D., Maurer, M. S., Joseph, S. M., Rogers, J. G., Birati, E. Y., Rame, J. E., et al. (2015). Left atrial decompression pump for severe heart failure with preserved ejection fraction: theoretical and clinical considerations. JACC Heart Fail, 3(4), 275–282.CrossRefPubMed
31.
Kao, D. P., Lewsey, J. D., Anand, I. S., Massie, B. M., Zile, M. R., Carson, P. E., et al. (2015). Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure, 17(9), 925–935.CrossRefPubMedPubMedCentral
32.
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., et al. (2015). Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation, 131(3), 269–279.CrossRefPubMed
33.
34.
Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118.CrossRefPubMed
35.
Gulshan, V., Peng, L., Coram, M., Stumpe, M. C., Wu, D., Narayanaswamy, A., et al. (2016). Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA, 316(22), 2402–2410.CrossRefPubMed
36.
Miotto, R., Li, L., Kidd, B. A., & Dudley, J. T. (2016). Deep patient: an unsupervised representation to predict the future of patients from the electronic health records. Scientific Reports, 6, 26094.CrossRefPubMedPubMedCentral
37.
Paulus, W. J., & Tschope, C. (2013). A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology, 62(4), 263–271.CrossRefPubMed
38.
Franssen, C., Chen, S., Unger, A., Korkmaz, H. I., De Keulenaer, G. W., Tschope, C., et al. (2016). Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail, 4(4), 312–324.CrossRefPubMed
39.
Hall, G., Rowell, J., Farinelli, F., Gbadegesin, R. A., Lavin, P., Wu, G., et al. (2014). Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. American Journal of Physiology. Renal Physiology, 306(12), F1442–F1450.CrossRefPubMedPubMedCentral
40.
Hidalgo, C., Saripalli, C., & Granzier, H. L. (2014). Effect of exercise training on post-translational and post-transcriptional regulation of titin stiffness in striated muscle of wild type and IG KO mice. Archives of Biochemistry and Biophysics, 552-553, 100–107.CrossRefPubMed
41.
Hoke, N. N., Salloum, F. N., Kass, D. A., Das, A., & Kukreja, R. C. (2012). Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. Stem Cells, 30(2), 326–335.CrossRefPubMed
42.
Yin, J., Kukucka, M., Hoffmann, J., Sterner-Kock, A., Burhenne, J., Haefeli, W. E., et al. (2011). Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circulation. Heart Failure, 4(2), 198–206.CrossRefPubMed
43.
Anjan, V. Y., Loftus, T. M., Burke, M. A., Akhter, N., Fonarow, G. C., Gheorghiade, M., et al. (2012). Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. The American Journal of Cardiology, 110(6), 870–876.CrossRefPubMedPubMedCentral
44.
45.
Khan, A. M., Cheng, S., Magnusson, M., Larson, M. G., Newton-Cheh, C., McCabe, E. L., et al. (2011). Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. The Journal of Clinical Endocrinology and Metabolism, 96(10), 3242–3249.CrossRefPubMedPubMedCentral
46.
Cheng, S., Fox, C. S., Larson, M. G., Massaro, J. M., McCabe, E. L., Khan, A. M., et al. (2011). Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. The American Journal of Cardiology, 108(7), 979–984.CrossRefPubMedPubMedCentral
47.
Wang, T. J. (2012). The natriuretic peptides and fat metabolism. The New England Journal of Medicine, 367(4), 377–378.CrossRefPubMed
48.
Newton-Cheh, C., Larson, M. G., Vasan, R. S., Levy, D., Bloch, K. D., Surti, A., et al. (2009). Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nature Genetics, 41(3), 348–353.CrossRefPubMedPubMedCentral
49.
Gupta, D. K., de Lemos, J. A., Ayers, C. R., Berry, J. D., & Wang, T. J. (2015). Racial differences in natriuretic peptide levels: the Dallas heart study. JACC Heart Fail, 3(7), 513–519.CrossRefPubMedPubMedCentral
50.
Lam, C. S., Cheng, S., Choong, K., Larson, M. G., Murabito, J. M., Newton-Cheh, C., et al. (2011). Influence of sex and hormone status on circulating natriuretic peptides. Journal of the American College of Cardiology, 58(6), 618–626.CrossRefPubMedPubMedCentral
51.
Obokata, M., Reddy, Y. N., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017). Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. doi:10.​1161/​CIRCULATIONAHA.​116.​026807.
52.
Anand, I. S., Claggett, B., Liu, J., Shah, A. M., Rector, T. S., Shah, S. J., et al. (2017). Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail, 5(4), 241–252.CrossRefPubMed
53.
Shah, S. J., Aistrup, G. L., Gupta, D. K., O’Toole, M. J., Nahhas, A. F., Schuster, D., et al. (2014). Ultrastructural and cellular basis for the development of abnormal myocardial mechanics during the transition from hypertension to heart failure. American Journal of Physiology. Heart and Circulatory Physiology, 306(1), H88–100.CrossRefPubMed
54.
Hong, T., & Shaw, R. M. (2017). Cardiac T-tubule microanatomy and function. Physiological Reviews, 97(1), 227–252.CrossRefPubMed
55.
Shah, S. J., & Wasserstrom, J. A. (2012). Increased arterial wave reflection magnitude: a novel form of stage B heart failure? Journal of the American College of Cardiology, 60(21), 2178–2181.CrossRefPubMed
56.
Riggs, K., Ali, H., Taegtmeyer, H., & Gutierrez, A. D. (2015). The use of SGLT-2 inhibitors in type 2 diabetes and heart failure. Metabolic Syndrome and Related Disorders, 13(7), 292–297.CrossRefPubMedPubMedCentral
57.
Unger, E. D., Dubin, R. F., Deo, R., Daruwalla, V., Friedman, J. L., Medina, C., et al. (2016). Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 18(1), 103–112.CrossRefPubMed
58.
Akmal, M., Barndt, R. R., Ansari, A. N., Mohler, J. G., & Massry, S. G. (1995). Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney International, 47(1), 158–163.CrossRefPubMed
59.
Polsinelli, V. B., & Shah, S. J. (2017). Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opinion on Pharmacotherapy, 18(4), 399–409.CrossRefPubMed
Metadaten
Titel
Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview
verfasst von
Sanjiv J. Shah
Publikationsdatum
05.06.2017
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 3/2017
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-017-9756-y

Weitere Artikel der Ausgabe 3/2017

Journal of Cardiovascular Translational Research 3/2017 Zur Ausgabe

Review

Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 1): Physiologic and Technical Considerations

Review

Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes

Original Article

Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction

Erratum

Erratum to: Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 1): Physiologic and Technical Considerations

Original Article

Text Mining of the Electronic Health Record: An Information Extraction Approach for Automated Identification and Subphenotyping of HFpEF Patients for Clinical Trials

Original Article

Phenotype-Specific Association of Single-Nucleotide Polymorphisms with Heart Failure and Preserved Ejection Fraction: a Genome-Wide Association Analysis of the Cardiovascular Health Study

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

24.04.2024 | Adipositas | Nachrichten

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 | ACC 2024 | Nachrichten

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen